NeOnc Technologies Reports Third Quarter 2026 Financial Results
NeOnc Technologies Holdings, Inc. announced its financial results for the third quarter ended September 30, 2026, alongside updates on its clinical development programs.
Stocks · News reference
NeOnc Technologies Signs Memorandum of Understanding with Department of Health – Abu Dhabi
NeOnc Technologies Holdings, Inc. has entered into a nonbinding Memorandum of Understanding with the Department of Health – Abu Dhabi to collaborate on oncology and CNS therapeutic research.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
Filed: 2026-11-05 AccNo: 0001829126-26-012024 Size: 239 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
NeOnc Technologies Q3 EPS $(0.28) Misses $(0.24) Estimate
NeOnc Technologies Holdings, Inc. Files Form 10-Q for Period Ending September 30, 2026
NeOnc Technologies Holdings, Inc. submitted its quarterly financial report (Form 10-Q) to the SEC for the period ending September 30, 2026.
NeOnc Is Putting Two Brain Cancer Programs on the Global Stage
NeOnc Technologies Holdings (NASDAQ: NTHI), a clinical-stage biopharmaceutical company, will present data from two investigational brain cancer programs—intranasal NEO100 and oral NEO212—at the Society for Neuro-Oncology annual meeting on November 13, 2026. The company is advancing ambitious plans for a 500-patient international clinical trial across 30 hospitals in three countries, leveraging innovative drug delivery approaches and AI-assisted tumor modeling technology.
NeOnc Technologies to Present Clinical Data at Society for Neuro-Oncology Annual Meeting
NeOnc Technologies Holdings, Inc. announced it will present updated clinical data for its intranasal NEO100 and oral NEO212 programs at the 31st Annual Meeting of the Society for Neuro-Oncology.